Arycs Technologies | $24,000,000 | (Mar 13, 2026)
Ezra(2) | $8,000,000 | (Mar 13, 2026)
Freestyle | $10,000,000 | (Mar 13, 2026)
Sedivention GmbH
Germany
- Straßlach-Dingharting
- 03/12/2024
- Pre-Seed
- $839,204
Sedivention develops a break-through, widely applicable, device for interventional obesity therapy. Hunger is transmitted from the stomach to the brain by the gastric trunks of the vagal nerve. Sedivention is developing a cryo-balloon freezing the gastric branches of the vagal nerve from inside the stomach, in a procedure comparable to gastroscopy. The ambulatory intervention takes approximately 20 min. The costs of the intervention are far below costs of bariatric surgery without surgical morbidity and complications. In brief: Sedivention develops the first long-term effective, scalable therapy for obesity: No scars, no pain, no surgical complications, no access barriers at an affordable price. Obesity causes over 400.000 deaths yearly in the US alone and costs of more than 2.0 trillion $US worldwide. According to the WHO obesity Atlas 2022, there will be 1 billion obese persons worldwide in 2030.
- Industry Medical Equipment Manufacturing
- Website https://www.sedivention.com/
- LinkedIn https://www.linkedin.com/company/sedivention-gmbh/
Related People
Ute Dr. med. NollertFounder
Germany -
Straßlach-Dingharting, Bavaria
I am a consultant anesthesiologist, affiliated to the Sana Klinik München. In 2021, I founded sedivention, a medtech company, that develops a device for interventional obesity therapy.
Mantis Space | $10,000,000 | (Mar 13, 2026)
Monteris Medical | $28,000,000 | (Mar 13, 2026)
Gumloop | $50,000,000 | (Mar 13, 2026)
Combat Medical Ltd | $3,472,639 | (Mar 13, 2026)
Qurrent | $15,000,000 | (Mar 13, 2026)
Waiv, formerly Owkin Dx | $33,000,000 | (Mar 13, 2026)
Carefam | $14,500,000 | (Mar 13, 2026)
Option Circle | $3,000,000 | (Mar 12, 2026)
AgentMail (YC S25) | $6,000,000 | (Mar 12, 2026)